COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Adenine
/ analogs & derivatives
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections
/ diagnosis
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ complications
Male
Middle Aged
Pandemics
Piperidines
Pneumonia, Viral
/ diagnosis
Prognosis
Protein Kinase Inhibitors
/ pharmacology
Pyrazoles
/ pharmacology
Pyrimidines
/ pharmacology
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Surveys and Questionnaires
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
06
2020
accepted:
30
06
2020
revised:
21
06
2020
pubmed:
11
7
2020
medline:
9
9
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Identifiants
pubmed: 32647324
doi: 10.1038/s41375-020-0959-x
pii: 10.1038/s41375-020-0959-x
pmc: PMC7347048
doi:
Substances chimiques
Antineoplastic Agents
0
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2363Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : Investigator Grant #20246
Pays : International
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : Special Program on Metastatic Disease - 5 per mille #21198
Pays : International
Références
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
doi: 10.1056/NEJMoa2001017
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, et al. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection. Clin Infect Dis. 2020:ciaa523. https://doi.org/10.1093/cid/ciaa523 .
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130:2620–9.
doi: 10.1172/JCI137244
England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Rev. 2020:100707. https://doi.org/10.1016/j.blre.2020.100707 .
Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a nationwide analysis of China. Eur Respir J. 2020;55:2000562.
doi: 10.1183/13993003.00562-2020
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45.
doi: 10.1038/s41375-020-0836-7
Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:904–13.
doi: 10.1016/S1470-2045(20)30310-7
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.
pubmed: 32345594
pmcid: 7309152
Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:893–903.
doi: 10.1016/S1470-2045(20)30309-0
Martín-Moro F, Marquet J, Piris M, Michael BM, Saez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–20.
doi: 10.1111/bjh.16801
Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020;34:1954–6.
doi: 10.1038/s41375-020-0870-5
Jin XH, Zheng KI, Pan KH, Xie YP, Zheng MH. COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematol. 2020;7:e351–e2.
doi: 10.1016/S2352-3026(20)30074-0
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81.
doi: 10.1182/blood-2015-03-567388
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612–21.
doi: 10.1182/blood-2012-09-457531
Maffei R, Maccaferri M, Arletti L, Fiorcari S, Benatti S, Potenza L, et al. Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections. Blood Rev. 2020;40:100635.
doi: 10.1016/j.blre.2019.100635
Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Gobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect again pulmonary injury in COVID-19-infected patients. Blood. 2020;135:1912–5.
doi: 10.1182/blood.2020006288
Cuneo A, Scarfo L, Reda G, Varettoni M, Quaglia FM, Marchetti M, et al. Chronic lymphocytic leukemia management in italy during the COVID-19 Pandemic. A campus CLL report. Blood. 2020:2020006854. https://doi.org/10.1182/blood.2020006854 .
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.
doi: 10.1182/blood-2017-09-806398
Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, et al. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 Pandemic. HemaSphere. 2020;4:e432. https://doi.org/10.1097/HS9.0000000000000432
doi: 10.1097/HS9.0000000000000432
Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5:eabd0110.
doi: 10.1126/sciimmunol.abd0110